Evidence map›Paper›PMID 41158705›Full record

ArticleMolecular and clinical oncology2025

Liver metastasis surgery followed by radical treatment for pancreatic ductal adenocarcinoma: A case report.

Taiki Tsuji, Makoto Takahashi, Kaoruko Funakoshi, Taku Higashihara, Tatsuya Hayashi, Haruka Okada, Junko Araki, Natsuki Miura, Yasuhiro Morita

Abstract readCase Reports
In one paragraph

Article in Molecular and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Taiki TsujiDepartment of Surgery, Tokyo Metropolitan Tama Medical Center, Tokyo 183-8524, Japan.
Makoto TakahashiDepartment of Surgery, Tokyo Metropolitan Tama Medical Center, Tokyo 183-8524, Japan.
Kaoruko FunakoshiDepartment of Surgery, Tokyo Metropolitan Tama Medical Center, Tokyo 183-8524, Japan.
Taku HigashiharaDepartment of Surgery, Tokyo Metropolitan Tama Medical Center, Tokyo 183-8524, Japan.
Tatsuya HayashiDepartment of Surgery, Tokyo Metropolitan Tama Medical Center, Tokyo 183-8524, Japan.
Haruka OkadaDepartment of Pathology, Tokyo Metropolitan Tama Medical Center, Tokyo 183-8524, Japan.
Junko ArakiDepartment of Radiology, Tokyo Metropolitan Tama Medical Center, Tokyo 183-8524, Japan.
Natsuki MiuraDepartment of Gastroenterology, Tokyo Metropolitan Tama Medical Center, Tokyo 183-8524, Japan.
Yasuhiro MoritaDepartment of Surgery, Tokyo Metropolitan Tama Medical Center, Tokyo 183-8524, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prognosis of patients with pancreatic ductal adenocarcinoma (PDAC) with liver metastasis is poor; therefore, chemotherapy is often selected instead of surgical intervention. However, there are some reports of cases becoming resectable after multidisciplinary treatment. On the other hand, there have been a few cases of long-term survival in which liver metastases were resected first, followed by prolonged chemotherapy and subsequent resection of the primary tumor. The present study describes the case of a patient with PDAC in which a liver metastasis was resected first, followed by chemotherapy and subsequent resection of the primary tumor, resulting in long-term survival. Briefly, a 72-year-old man diagnosed with resectable PDAC was scheduled to undergo subtotal stomach-preserving pancreaticoduodenectomy after neoadjuvant chemotherapy. Intraoperatively, a liver metastasis was detected, and partial hepatectomy was performed. The patient received 13 cycles of modified 5-fluorouracil, leucovorin, irinotecan and oxaliplatin. A subtotal stomach-preserving pancreaticoduodenectomy was then performed when no new lesions were observed. The patient received S-1 as adjuvant chemotherapy for 1 year postoperatively. Currently, 5 years after diagnosis, and 4 years and 3 months after the last surgery, the patient has experienced no recurrence. In conclusion, even if curative surgery is not possible because of a liver metastasis at the time of the initial operation, some patients may achieve long-term survival through resection, and preoperative and postoperative chemotherapy.

Indexed as

chemotherapyliver metastasisPDACsurgery

Identifiers

PMID41158705
PMCPMC12557690

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.